March 7, 2012
"Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday [at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle] highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) interventions," HIV Medicine Association Executive Director Andrea Weddle writes in this guest post in the Center for Global Health Policy's "Science Speaks" blog. "The FEM-PrEP study was conducted to evaluate the protective effect of a daily oral dose of emtricitabine/tenofovir disoproxil fumerate (FTC/TDF) among African women, but was halted early, in April 2011," because of "interim data analysis showing similar rates of new HIV infections among women taking daily FTC/TDF and the placebo arm," Weddle notes. Van Damme said blood monitoring did not show levels of the drug consistent with self-reported adherence rates, according to Weddle (3/6).
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|